Towa Snaps Up Sunsho For Value-Added Advantage
Acquisition Of Japanese Firm From Carlyle Will Add Technologies To Help Towa Diversify
Executive Summary
Towa Pharmaceutical has struck a deal to acquire fellow Japanese firm Sunsho Pharmaceutical in a move that Towa says will help it to diversify by developing value-added products.
You may also be interested in...
Some Uncertainty Ahead For Towa Following Strong Financial Year
Towa performed well during the financial year ended 31 March, delivering a ¥15.9bn profit, but questions remain about the impact of Japan’s NHI drug price revision and its acquisition of Sunsho Pharmaceuticals going forward.
Asia Deal Watch: Cytokinetics Licenses China Rights For Omecamtiv To Ji Xing
Plus deals involving Sun's SPARC/Visiox, Twist/Sosei, BeiGene, Leads Biolabs, Qilu/Arbutus, Hansoh/Keros, Simcere/Avilex and Cytokinetics/Ji Xing.
Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako
Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.